摘要: … These pharmacokinetic–pharmacodynamic (PK/PD) relationships have become available … use of PK/PD relationships are discussed to show the applicability of PK/PD relationships in …
elsevier.com
sci-hub.se 参考文章(13)
W A Craig, Choosing an antibiotic on the basis of pharmacodynamics. Ear, nose, & throat journal. ,vol. 77, pp. 7- 12 ,(1998)
Angela D. M. Kashuba, Anne N. Nafziger, George L. Drusano, Joseph S. Bertino, Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria Antimicrobial Agents and Chemotherapy. ,vol. 43, pp. 623- 629 ,(1999) , 10.1128/AAC.43.3.623
Sandra L. Preston, Pharmacodynamics of Levofloxacin JAMA. ,vol. 279, pp. 125- 129 ,(1998) , 10.1001/JAMA.279.2.125
David Andes, William A. Craig, PHARMACOKINETICS AND PHARMACODYNAMICS OF OUTPATIENT INTRAVENOUS ANTIMICROBIAL THERAPY Infectious Disease Clinics of North America. ,vol. 12, pp. 849- 860 ,(1998) , 10.1016/S0891-5520(05)70024-6
Johan W. Mouton, Daan J. Touw, Alphonsus M. Horrevorts, Alexander A.T.M.M. Vinks, Comparative pharmacokinetics of the carbapenems: clinical implications. Clinical Pharmacokinectics. ,vol. 39, pp. 185- 201 ,(2000) , 10.2165/00003088-200039030-00002
David R. Andes, William A. Craig, Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infectious Disease Clinics of North America. ,vol. 13, pp. 595- 618 ,(1999) , 10.1016/S0891-5520(05)70096-9
CHARLES H. NIGHTINGALE, Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatric Infectious Disease Journal. ,vol. 16, pp. 438- 443 ,(1997) , 10.1097/00006454-199704000-00027
Jerome J. Schentag, Kristin K. Gilliland, Joseph A. Paladino, What have we learned from pharmacokinetic and pharmacodynamic theories Clinical Infectious Diseases. ,vol. 32, ,(2001) , 10.1086/319375
J. W. Mouton, Use of the t > MIC to choose between different dosing regimens of beta-lactam antibiotics Journal of Antimicrobial Chemotherapy. ,vol. 47, pp. 500- 501 ,(2001) , 10.1093/JAC/47.4.500
G. L. Drusano, S. L. Preston, C. Hardalo, R. Hare, C. Banfield, D. Andes, O. Vesga, W. A. Craig, Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint Antimicrobial Agents and Chemotherapy. ,vol. 45, pp. 13- 22 ,(2001) , 10.1128/AAC.45.1.13-22.2001